The Protective Role of Bmal1-Regulated Autophagy Mediated by HDAC3/SIRT1 Pathway in Myocardial Ischemia/Reperfusion Injury of Diabetic Rats
ConclusionBased on these findings, the disordered HDAC3/SIRT1 circuit (upregulated HDAC3 and downregulated SIRT1 levels) plays an important role in aggravating myocardial IR injury in diabetic rats by downregulating Bmal1-mediated autophagy. Treatments targeting HDAC3/SIRT1 to activate the autophagy may represent a novel strategy to alleviate myocardial IR injury in diabetes. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 23, 2021 Category: Cardiology Source Type: research

Generation of a Novel In Vitro Model to Study Endothelial Dysfunction from Atherothrombotic Specimens
ConclusionsCEO cells can be reliably isolated and cultured from thrombectomy specimens in patients with acute coronary syndrome. Compared to controls, patient-derived coronary endothelial cells had impaired capacity to proliferate, migrate, and contribute to angiogenesis. CEO cells could be used to identify novel therapeutic targets to enhance endothelial function and prevent acute coronary syndromes. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 20, 2021 Category: Cardiology Source Type: research

Targeting Human lncRNAs for Treating Cardiometabolic Diseases
ConclusionsDysregulation of lncRNAs has been associated with human diseases, including cancer, neurodegenerative, and cardiometabolic diseases. However, as lncRNAs are usually much less conserved than mRNAs at the sequence level, most human lncRNAs are either primate or human specific. The pathophysiological significance of human lncRNAs is still mostly unclear due to the persistent limitations in studying human-specific genes. This review will focus on recent discoveries showing human lncRNAs ’ roles in regulating metabolic homeostasis and the potential of targeting this unique group of genes for treatment of cardio...
Source: Cardiovascular Drugs and Therapy - February 20, 2021 Category: Cardiology Source Type: research

Translating genetic association of lipid levels for biological and clinical application
ConclusionsLipids are one of the most successful group of traits in the era of genome-wide genetic discovery for identification of novel loci and plausible drug targets. However, a substantial fraction of lipid trait heritability remains unexplained. Further analysis of diverse ancestries and state of the art methods for association locus refinement could potentially reveal some of this missing heritability and increase the clinical application of the genomic association results. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 19, 2021 Category: Cardiology Source Type: research

A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database
ConclusionPharmacovigilance studies allow an essential opportunity to evaluate the safety profile of CVD medications in clinical practice. Additional research is needed to evaluate these reported safety concerns for recently approved CVD medications. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 18, 2021 Category: Cardiology Source Type: research

Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19
ConclusionThis large multicenter retrospective of Covid-19 patients with hypertension found a reduced mortality among CCB and beta-blockers users, suggesting a putative protective effect. Our findings did not show any association between the use of renin-angiotensin-aldosterone system inhibitors and the risk of in-hospital death. Although they need to be confirmed in further studies, these results support the continuation of antihypertensive agents in patients with Covid-19, in line with the current guidelines. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 17, 2021 Category: Cardiology Source Type: research

Aspirin Versus Dual Antiplatelet Therapy in Patients Undergoing Trans-Catheter Aortic Valve Implantation, Updated Meta-Analysis
ConclusionsThis meta-analysis supports the use of aspirin as the optimal antiplatelet strategy following TAVI procedures in reducing bleeding without an increase in ischemic events compared with dual antiplatelet therapy. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 15, 2021 Category: Cardiology Source Type: research

Aspirin Alone Versus Dual Antiplatelet Therapy after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis
AbstractBackgroundThe current American College of Cardiology and American Heart Association (ACC/AHA) guidelines recommend dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 6  months followed by lifelong aspirin after transcatheter aortic valve replacement (TAVR). However, studies that have DAPT with aspirin following TAVR have questioned this recommendation as DAPT has been associated with more bleeding events compared to aspirin. We performed a systematic review and m eta-analysis of all the RCTs comparing DAPT (aspirin plus clopidogrel) with aspirin alone as antithrombotic treatment following transc...
Source: Cardiovascular Drugs and Therapy - February 11, 2021 Category: Cardiology Source Type: research

Cost-Effectiveness of Endovascular Versus Open Repair of Abdominal Aortic Aneurysm: A Systematic Review
ConclusionAccording to the results, the EVAR technique has been more cost-effective than OSR for high-risk patients, but the need for continuous follow-up, increased costs, and re-intervention over the long term and for low-risk patients has reduced the cost-effectiveness of this method. As the health systems vary among different countries (i.e. quality of care, cost of devices, etc.), and due to the heterogeneity of studies in terms of the follow-up period, time horizon, and threshold, all of which are inherent features of economic evaluation, generalizing the results should be done with much caution, and policymaking mus...
Source: Cardiovascular Drugs and Therapy - February 9, 2021 Category: Cardiology Source Type: research

LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry
AbstractPurposeLow-density lipoprotein (LDL) cholesterol reduction by statin therapy is dose-dependent, varies among different statins, and has wide inter-individual variability. The present study aimed to compare mean LDL cholesterol reduction and its variability achieved with different doses of the three statins most frequently used in monotherapy or combined with ezetimibe in a real clinical setting.MethodsOf 5620 cases with primary hypercholesterolemia on the Spanish Arteriosclerosis Society Registry, 1004 with non-familial hypercholesterolemia and complete information on drug therapy and lipid profile were included.Re...
Source: Cardiovascular Drugs and Therapy - February 8, 2021 Category: Cardiology Source Type: research

Effects of OP2113 on Myocardial Infarct Size and No Reflow in a Rat Myocardial Ischemia/Reperfusion Model
AbstractPurposeThe present study was to determine whether OP2113 could limit myocardial infarction size and the no-reflow phenomenon in a rat myocardial ischemia/reperfusion model.MethodsRat heart –isolated mitochondria (RHM) were used to investigate mitochondrial respiration and mitochondrial reactive oxygen species (mtROS) generation both in normal conditions and in ischemia/reperfusion-mimicking conditions (using high concentrations of succinate). Human skeletal muscle myoblasts (HSMM) i n culture were used to investigate the cellular intermittent deprivation in energy substrates and oxygen as reported in ischemia...
Source: Cardiovascular Drugs and Therapy - February 8, 2021 Category: Cardiology Source Type: research

Correction to: The Effect of Enhanced External Counterpulsation on Platelet Aggregation in Patients with Coronary Heart Disease
A Correction to this paper has been published:https://doi.org/10.1007/s10557-021-07152-8 (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 5, 2021 Category: Cardiology Source Type: research

Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4 –5 Chronic Kidney Disease or on Dialysis
ConclusionsCurrent evidence suggests that rivaroxaban or apixaban are safe and at least as effective as warfarin in patients with AF and stage 4 –5 CKD or on dialysis. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 4, 2021 Category: Cardiology Source Type: research

The Interface of Therapeutics and Genomics in Cardiovascular Medicine
AbstractPharmacogenomics has a burgeoning role in cardiovascular medicine, from warfarin dosing to antiplatelet choice, with recent developments in sequencing bringing the promise of personalised medicine ever closer to the bedside. Further scientific evidence, real-world clinical trials, and economic modelling are needed to fully realise this potential. Additionally, tools such as polygenic risk scores, and results from Mendelian randomisation analyses, are only in the early stages of clinical translation and merit further investigation. Genetically targeted rational drug design has a strong evidence base and, due to the ...
Source: Cardiovascular Drugs and Therapy - February 2, 2021 Category: Cardiology Source Type: research

A 10-Year Aortic Center Experience with Hybrid Repair of Chronic “Residual” Aortic Dissection After Type A Repair
ConclusionIn a high-volume aortic center, hybrid repair of RAD is associated with good anatomical results and a low risk of perioperative morbidity and mortality, including that of patients treated in zone 0. A redo replacement of the ascending aortic segment is sometimes necessary to provide a safer proximal landing zone and reduce the risk of type 1 endoleak after TEVAR. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 2, 2021 Category: Cardiology Source Type: research

Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis
AbstractPurposeIt was aimed to determine the aggregated risk of MACE (major adverse cardiovascular events) in stable CAD patients carryingCYP2C19 LoF alleles taking clopidogrel.MethodsLiterature was searched in different databases for relevant studies. Aggregated risk was estimated using a fixed/random effect model wherep-value
Source: Cardiovascular Drugs and Therapy - February 1, 2021 Category: Cardiology Source Type: research

Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease —Perspective from the Veterans Affair Healthcare System
AbstractPurposeStatin-associated side effects (SASEs) can limit statin adherence and present a potential barrier to optimal statin utilization. How standardized reporting of SASEs varies across medical facilities has not been well characterized.MethodsWe assessed facility-level variation in SASE reporting among patients with atherosclerotic cardiovascular disease receiving care across the Veterans Affairs (VA) healthcare system from October 1, 2014, to September 30, 2015. The facility rates for SASE reporting were expressed as cases per 1000 patients with ASCVD. Facility-level variation was determined using hierarchical re...
Source: Cardiovascular Drugs and Therapy - February 1, 2021 Category: Cardiology Source Type: research

One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration
ConclusionsDespite the novel EPC capture technology, COMBO stent PCI was associated with somewhat greater risk of 1-year TLF in ACS than in non-ACS patients, without significant differences in stent thrombosis. No differences were observed in 1-year TLF among ACS subtypes. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 30, 2021 Category: Cardiology Source Type: research

Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance
AbstractAn elevated plasma low-density lipoprotein cholesterol (LDL-C) level is a well-established atherosclerotic cardiovascular disease (ACSVD) risk factor. Randomized studies with statins (alone or in combination with other lipid-lowering drugs) have demonstrated their clinical efficacy in lowering LDL-C. Several classes of new, non-statin agents have been successfully studied and used (e.g., ezetimibe and inhibitors of proprotein convertase subtilisin/kexin type 9 [i-PSCK9]). However, many high ACSVD risk patients remain at a high residual cardiovascular risk, with at least 10% being statin intolerant. Bempedoic acid (...
Source: Cardiovascular Drugs and Therapy - January 27, 2021 Category: Cardiology Source Type: research

Chronic Naltrexone Therapy Is Associated with Improved Cardiac Function in Volume Overloaded Rats
ConclusionOpioid receptor blockade by naltrexone leads to improved LV function and decreases in rBNP-45 and angiotensin-2 plasma levels. In parallel, naltrexone resulted in opioid receptor mRNA downregulation and an elevated intrinsic tone of endogenous opioid peptides possibly reflecting a potentially cardiodepressant effect of the cardiac opioid system during volume overload. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 23, 2021 Category: Cardiology Source Type: research

The Effect of Enhanced External Counterpulsation on Platelet Aggregation in Patients with Coronary Heart Disease
ConclusionEECP therapy is favorable for lowering platelet aggregation in patients with CHD, especially the AA-induced platelet aggregation ratio. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 21, 2021 Category: Cardiology Source Type: research

Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis
AbstractBackgroundOral sodium zirconium cyclosilicate (SZC) is a novel potassium binder capable of achieving a rapid reduction of serum potassium (sK+) and maintaining a long-term normokalemia. We undertook a meta-analysis to summarize and evaluate the effects surrounding SZC in patients with hyperkalemia.MethodWe searched data sources from MEDLINE (from 1950 to Sep 2020), EMBASE (from 1970 to Sep 2020), and the Cochrane Library database (from 1950 to Sep 2020) for eligible studies. All randomized controlled trials (RCTs) regarding comparison of therapeutic effects of SZC in hyperkalemia participants were included.ResultsS...
Source: Cardiovascular Drugs and Therapy - January 18, 2021 Category: Cardiology Source Type: research

HIV Protein Tat Induces Macrophage Dysfunction and Atherosclerosis Development in Low-Density Lipoprotein Receptor –Deficient Mice
ConclusionsOur findings reveal atherogenic effects of HIV protein Tat in vivo and demonstrate a pivotal role of myeloid IKK β in Tat-driven atherogenesis. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 18, 2021 Category: Cardiology Source Type: research

P-Selectin Glycoprotein Ligand-1 Deficiency Protects Against Aortic Aneurysm Formation Induced by DOCA Plus Salt
ConclusionPSGL-1 deficiency is protective against inflammatory cells migration and recruitment in the condition of AA through attenuation of leukocyte –endothelial adhesion. Inhibition of PSGL-1 may be a potential therapeutic target for the prevention and treatment of human AA. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 11, 2021 Category: Cardiology Source Type: research

Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis
ConclusionThe benefit-risk profile of NOACs seems preserved in (morbidly) obese AF patients and patients with low body weight. However, more data are needed on underweight AF patients (BMI
Source: Cardiovascular Drugs and Therapy - January 11, 2021 Category: Cardiology Source Type: research

Heart Rate Reduction with Ivabradine Prevents Cardiac Rupture after Myocardial Infarction in Mice
ConclusionOur findings suggest that HR reduction with IVA prevents cardiac rupture after MI. This may be particularly effective in MI patients with a high HR who are either unable to adequately tolerate β-blockers or whose HR remains high despite receiving β-blockers. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 7, 2021 Category: Cardiology Source Type: research

Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant
ConclusionCYP2J2 dominated the hydroxylation of rivaroxaban, which may provide new insight into clinical drug interactions involving rivaroxaban. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 7, 2021 Category: Cardiology Source Type: research

Ivabradine in Cardiovascular Disease Management Revisited: a Review
AbstractIvabradine is a unique agent that is distinct from beta-blockers and calcium channel blockers as it reduces heart rate without affecting myocardial contractility or vascular tone. Ivabradine is a use-dependent inhibitor targeting the sinoatrial node. It is approved for use in the United States as an adjunct therapy for heart rate reduction in patients with heart failure with reduced ejection fraction. In this scenario, ivabradine has demonstrated improved clinical outcomes due to reduction in heart failure readmissions. However, there has been conflicting evidence from prospective studies and randomized controlled ...
Source: Cardiovascular Drugs and Therapy - January 7, 2021 Category: Cardiology Source Type: research

Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm
AbstractThe coronavirus disease 19 (COVID-19) pandemic poses a serious global threat to human health and the economy. Based on accumulating evidence, its continuous progression involves not only pulmonary injury but also damage to the cardiovascular system due to intertwined pathophysiological risks. As a point of convergence in the pathophysiologic process between COVID-19 and heart failure (HF), cytokine storm induces the progression of COVID-19 in patients presenting pre-existing or new onset myocardial damage and even HF. Cytokine storm, as a trigger of the progression of HF in patients with COVID-19, has become a nove...
Source: Cardiovascular Drugs and Therapy - January 6, 2021 Category: Cardiology Source Type: research

Effects of Angiotensin II Receptor Blockers on Ventricular Hypertrophy in Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials
ConclusionThis meta-analysis showed that ARB treatment is not associated with reduced left ventricular mass nor remarkable LVEF change among patients with hypertrophic cardiomyopathy. Further studies with a larger number of patients will be required to confirm these findings. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 6, 2021 Category: Cardiology Source Type: research

Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation
ConclusionsIn this large cohort of obese Veterans Health Administration system patients, the use of DOACs resulted in lower hemorrhagic complications than warfarin while maintaining efficacy on ischemic stroke prevention. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 6, 2021 Category: Cardiology Source Type: research

Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7
AbstractPurposeWe investigated facility-level variation in the use and adherence with antiplatelets and statins among patients with premature and extremely premature ASCVD.MethodsUsing the 2014 –2015 nationwide Veterans wIth premaTure AtheroscLerosis (VITAL) registry, we assessed patients with premature (age at first ASCVD event: males
Source: Cardiovascular Drugs and Therapy - January 5, 2021 Category: Cardiology Source Type: research

Pharmacologic Cardioversion in Patients with Paroxysmal Atrial Fibrillation: A Network Meta-Analysis
ConclusionOur network meta-analysis identified with sufficient power and consistency the most effective antiarrhythmics for pharmacologic cardioversion over different time settings, with vernakalant and flecainide exhibiting a safer and more efficacious profile toward faster cardioversion.Graphical abstract (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 5, 2021 Category: Cardiology Source Type: research

Matrix Metalloproteinases Repress Hypertrophic Growth in Cardiac Myocytes
ConclusionMMPs ’ inhibition promotes hypertrophic growth in cardiomyocytes in vitro. Therefore, MMPs in the healthy heart may be important players to repress cardiac hypertrophy. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 5, 2021 Category: Cardiology Source Type: research

Methotrexate Therapy Promotes Cell Coverage and Stability in in-Stent Neointima
ConclusionLow-dose MTX may be a key means of promoting early cell coverage via the inhibition of the inflammatory response and stability of neointima by targeting inflammatory pathways after stent implantation. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 4, 2021 Category: Cardiology Source Type: research

The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19
ConclusionsAmong hospitalized COVID-19 patients, LMWH use was associated with lower all-cause in-hospital mortality than non-LMWH users. The survival benefit was particularly significant among more severely ill patients. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - January 4, 2021 Category: Cardiology Source Type: research

Research Progress on Pulmonary Arterial Hypertension and the Role of the Angiotensin Converting Enzyme 2-Angiotensin-(1 –7)-Mas Axis in Pulmonary Arterial Hypertension
AbstractPulmonary arterial hypertension (PAH) is a progressive disease with a complex aetiology and high mortality. Functional and structural changes in the small pulmonary arteries lead to elevated pulmonary arterial pressure, resulting in right heart failure. The pathobiology of PAH is not fully understood, and novel treatment targets in PAH are desperately needed. The renin-angiotensin system is critical for maintaining homeostasis of the cardiovascular system. The system consists of the angiotensin converting enzyme (ACE)-angiotensin (Ang) II-angiotensin type 1 receptor (AT1R) axis and the ACE2-Ang-(1 –7)-Mas rec...
Source: Cardiovascular Drugs and Therapy - January 4, 2021 Category: Cardiology Source Type: research

The Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular Disease
AbstractPurposeCirculating endothelial progenitor cells (cEPCs) are vital to vascular repair by re-endothelialization. We aimed to explore the effect of proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9i) on cEPCs hypothesizing a possible pleiotropic effect.MethodsPatients with cardiovascular disease (CVD) were sampled for cEPCs at baseline and following the initiation of PCSK9i. cEPCs were assessed using flow cytometry by the expression of CD34(+)/CD133(+) and vascular endothelial growth factor receptor (VEGFR)-2(+), and by the formation of colony-forming units (CFUs) and production of VEGF.ResultsOur cohort...
Source: Cardiovascular Drugs and Therapy - January 4, 2021 Category: Cardiology Source Type: research

Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
AbstractBackgroundIn patients with acute coronary syndrome (ACS), angiotensin-converting enzyme (ACE) inhibitors are preferred over angiotensin receptor blockers (ARBs). However, in a recent pilot study, treatment with ACE inhibitors was associated with increased platelet reactivity compared to ARBs. Therefore, we sought to investigate the impact of renin-angiotensin-aldosterone system (RAAS) blockade with ACE inhibitors and ARBs on platelet aggregation in patients with ACS undergoing percutaneous coronary intervention.MethodsOn-treatment residual platelet reactivity in response to arachidonic acid (AA), adenosine diphosph...
Source: Cardiovascular Drugs and Therapy - December 18, 2020 Category: Cardiology Source Type: research

Toward Better Reproducibility in Experimental Research on New Agents for Pulmonary Hypertension. An Analysis of Data from Four Hundred Animal Studies
ConclusionsThe animal models of PH used for pre-clinical studies are diverse and there are several methodological items within the established protocols that can determine the obtained result.Graphical abstract (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - December 9, 2020 Category: Cardiology Source Type: research

Transforming Growth Factor- β and the Renin-Angiotensin System in Syndromic Thoracic Aortic Aneurysms: Implications for Treatment
AbstractThoracic aortic aneurysms (TAAs) are permanent pathological dilatations of the thoracic aorta, which can lead to life-threatening complications, such as aortic dissection and rupture. TAAs frequently occur in a syndromic form in individuals with an underlying genetic predisposition, such as Marfan syndrome (MFS) and Loeys-Dietz syndrome (LDS). Increasing evidence supports an important role for transforming growth factor- β (TGF-β) and the renin-angiotensin system (RAS) in TAA pathology. Eventually, most patients with syndromic TAAs require surgical intervention, as the ability of present medical treatment...
Source: Cardiovascular Drugs and Therapy - December 7, 2020 Category: Cardiology Source Type: research

BK Ca Channel Activation Attenuates the Pathophysiological Progression of Monocrotaline-Induced Pulmonary Arterial Hypertension in Wistar Rats
ConclusionThe use of a selective and potent opener to activate the BKCa channels promoted improvement of haemodynamic parameters and consequent prevention of RV maladaptive remodelling in rats with MCT-induced PAH. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - November 27, 2020 Category: Cardiology Source Type: research

Extracellular Vesicles Derived from Intermittent Hypoxia –Treated Red Blood Cells Impair Endothelial Function Through Regulating eNOS Phosphorylation and ET-1 Expression
ConclusionsThis study reveals a novel role of REVs in endothelial dysfunction under IH and dissects the relevant mechanism involved in this process, which will help to establish a comprehensive understanding of OSA or IH-related endothelial dysfunction from a new scope. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - November 26, 2020 Category: Cardiology Source Type: research

Assessment of Low LDL Cholesterol in Patients Treated by PCSK9 Inhibition: Comparison of Martin/Hopkins and Friedewald Estimations
AbstractPurposeRecent guidelines recommend further reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk populations. The use of proprotein convertase subtilisin/kexin type-9 inhibitors (PCSK9i) enables many patients to achieve profound reduction in LDL-C. However, in patients with low cholesterol, the commonly used Friedewald equation tends to underestimate LDL-C, which may result in undertreatment. We aimed to compare Friedewald LDL-C estimation with the more novel Martin/Hopkins method in PCSK9i-treated patients achieving low LDL-C.MethodsWe investigated high-risk patients treated by PCSK9i in whom Fried...
Source: Cardiovascular Drugs and Therapy - November 23, 2020 Category: Cardiology Source Type: research

Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis
AbstractPurposeWhether direct oral anticoagulants (DOACs) are more effective and safer than warfarin among Asian patients with non-valvular atrial fibrillation (NVAF) undergoing dialysis remains unclear.MethodsWe first compared the risks of ischemic stroke/systemic embolism (IS/SE) and major bleeding associated with DOACs compared with warfarin, in NVAF Asians undergoing dialysis using the Taiwan National Health Insurance Research Database (NHIRD) (Aim 1). Next, we searched PubMed and Medline from January 1, 2010 until January 31, 2020, to perform a systematic review and meta-analysis of all observational real-world studie...
Source: Cardiovascular Drugs and Therapy - November 19, 2020 Category: Cardiology Source Type: research

Eliminating Gender Disparities in Coronary Heart Disease Treatment: Are We There Yet?
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - November 18, 2020 Category: Cardiology Source Type: research

Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications
AbstractAtherosclerotic coronary artery disease has a complex pathogenesis which extends beyond cholesterol intimal infiltration. It involves chronic inflammation of the coronary artery wall driven by systemic and local activation of both the adaptive and innate immune systems, which can ultimately result in the rupture or erosion of atherosclerotic plaque, leading to thrombosis and myocardial infarction (MI). Despite current best practice care, including the widespread use of cholesterol-lowering statins, atherothrombotic cardiovascular events recur at alarming rates post-MI. To a large extent, this reflects residual infl...
Source: Cardiovascular Drugs and Therapy - November 10, 2020 Category: Cardiology Source Type: research

Polygenic Risk Score: Clinically Useful Tool for Prediction of Cardiovascular Disease and Benefit from Lipid-Lowering Therapy?
AbstractImprovement in risk prediction of atherosclerotic cardiovascular disease (ASCVD) using information on the genetic predisposition at an individual level might offer new possibilities for the successful management of such complex trait. Latest developments in genetic research with the conduction of genome-wide association studies have facilitated a broader utility of polygenic risk score (PRS) as a potent risk prognosticator, being strongly associated with future cardiovascular events. Although its discriminative ability beyond traditional risk factors is still a matter of controversy, PRS possesses at least comparab...
Source: Cardiovascular Drugs and Therapy - November 6, 2020 Category: Cardiology Source Type: research

miR-330-5p inhibits NLRP3 inflammasome-mediated myocardial ischaemia –reperfusion injury by targeting TIM3
ConclusionsOur study indicated that the miR-330-5p/TIM3 axis was involved in the regulatory mechanism of NLRP3 inflammasome-mediated myocardial inflammation. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - November 2, 2020 Category: Cardiology Source Type: research

Correction to: Fusion Imaging of X-ray and Transesophageal Echocardiography Improves the Procedure of Left Atrial Appendage Closure
The article “Fusion Imaging of X-ray and Transesophageal Echocardiography Improves the Procedure of Left Atrial Appendage Closure.” (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - October 27, 2020 Category: Cardiology Source Type: research